Pharmablue / Papers / Drugs Eligibility criteria for early access programs in France / Routine-Pharmacovigilance-PV-activities-–-2@2x-1.png

Routine-Pharmacovigilance-PV-activities-–-2@2x-1.png

Routine-Pharmacovigilance-PV-activities-–-2@2x-1.png

6 March 2025

Pharmablue

Pharmablue

Did you like this article? Share on social networks:

email linkedin twitter link
Exploitant for Innovative Pharma Companies

Associated News

10 Years of commitment to treating rare diseases

Rare diseases: At the core of our mission At PharmaBlue, we’ve spent the past decade...

Learn more
Ultimate Guide for European Early & Expanded Access Programs

Expanded Access is a treatment option that allows the use of an unauthorized medicine (investigational...

Learn more
Everything to know about exploitant status in France

About the "Exploitant" status French regulatory authorities require having an « Exploitant » authorized and...

Learn more